{
    "info": {
        "nct_id": "NCT06598371",
        "official_title": "A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors",
        "inclusion_criteria": "1. Diagnosed with one of the following tumor types:\n\n   1. Unresectable, incurable and/or metastatic histologically and/or cytologically confirmed cutaneous, acral, or unknown primary melanoma (Stage IIIC or Stage IV) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting, one of which includes treatment with anti-PD-1/PD-L1 inhibitor alone or in combination with anti-cytotoxic T lymphocyte associated protein 4 (anti-CTLA-4) inhibitor or in combination with anti-LAG-3 antibody.\n\n      Note: Up to 5 mucosal patients can be treated in the melanoma expansion cohort only.\n   2. Histologically and/or cytologically confirmed primary diagnosis of NSCLC which has progressed on at least 1 line and no more than 4 lines of prior therapy in the advanced/metastatic setting, including platinum-based chemotherapy and checkpoint inhibitor therapy (either given in combination or sequentially).\n\n   i. Participants with tumors that have known actionable molecular alteration such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS-1, B-Raf proto-oncogene (BRAF), rearranged during transfection (RET), MET and Kirsten Rat Sarcoma Virus (KRAS) must have progressed on standard directed molecular therapy in addition to platinum-based chemotherapy.\n\n   Note, the following do not count towards a line of prior therapy:\n   * Any therapy/regimen discontinued due to intolerance/tolerability issues\n   * Retreatment with the same class or previous class of treatment alone or in combination c. Locally advanced recurrent and/or metastatic histologically and/or cytologically confirmed HNSCC that has been previously treated with at least 1 and no more than 4 lines of prior therapy in the advanced/metastatic setting.\n\n     i. Participants must have received a platinum-containing chemotherapy regimen for the treatment of primary tumor in locally advanced, or metastatic setting d. Advanced, metastatic histologically and/or cytologically confirmed colorectal adenocarcinoma that has progressed following at least 1 and no more than 3 lines of prior therapy. Participants with dMMR/MSI-H or KRASG12C BRAF V600E mutation must have progressed on standard directed therapy.\n\n     e. Locally advanced, recurrent, or metastatic histologically and/or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.\n\n     f. Recurrent, metastatic, or persistent histologically and/or cytologically confirmed squamous cell carcinoma (SCC), adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.\n2. Resectable lesion for KSQ-004EX manufacturing (tumor ≥ 1.5 cm2 or at least 5 core needle biopsies)\n3. At least one measurable lesion per RECIST v1.1 (Eisenhauer 2009) following tumor resection for KSQ-004EX manufacturing Note: Lesions in previously irradiated areas should not be selected as a target lesion unless radiation treatment was ≥ 3 months prior, and there has been demonstrated disease progression in the lesion\n4. Age ≥ 18 years of age\n5. Life expectancy of ≥ 12 weeks\n6. Recovered to ≤ Grade 1 or Baseline toxicity (except alopecia, neuropathy, and endocrinopathies from prior immunotherapy) from prior therapy (per the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE])\n7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n8. Adequate bone marrow function defined as:\n\n   1. Absolute neutrophil count (ANC) of ≥ 1 × 109/L\n   2. Platelet count of ≥ 100.0 × 109/L\n   3. Hemoglobin of ≥ 9.0 g/dL\n9. Adequate renal function defined as calculated creatinine clearance (Cockcroft-Gault) ≥ 40 mL/min\n10. Adequate hepatic function defined as:\n\n    1. Total bilirubin ≤ 2.0 × upper limit of normal (ULN) unless associated with Gilbert's syndrome\n    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (or ≤ 5 × ULN in patients with liver metastases)\n11. Washout period from prior anticancer therapy(ies) of a minimum duration (excluding bridging therapy per concomitant medication, see Section 6.11) is required prior to the first study treatment (i.e., start of LDC therapy) as detailed below:\n\n    1. Targeted therapy: prior targeted therapy with an EGFR, ALK, receptor tyrosine kinase, or other-directed agent (eg, erlotinib, afatinib, osimertinib, crizotinib, ceritinib), is allowed provided the washout is a minimum of 7 days or 5 half-lives, whichever is longer prior to start of therapy (LDC)\n    2. Monoclonal antibodies with a washout of at least 21 days or 5 half-lives or whichever is longer\n    3. Chemotherapy: adjuvant, neoadjuvant or definitive chemotherapy/chemoradiation is allowed provided the washout is a minimum of 21 days or 5 half-lives, whichever is shorter\n    4. Radiation therapy: prior external beam radiation is allowed provided a minimum of 14 days have elapsed between the last dose of radiation and first study treatment (LDC)\n    5. Surgery: previous surgical procedure(s) is permitted provided that wound healing has occurred and at least 14 days have elapsed (for major operative procedures) prior to the first study treatment (LDC)\n12. Female participants who are women of childbearing potential (WOCP), (defined as physiologically and anatomically capable of becoming pregnant), confirmed of a negative pregnancy test and agreement to the use of a highly effective contraceptive method or at least 2 effective methods at the same time during study treatment period and for up to 3 months after study treatment (KSQ-004EX infusion). Male participants must be willing to use effective barrier contraception (ie, condoms) during the study treatment period and for up 3 months after study treatment (KSQ-004EX infusion)\n\n    a. This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following: i. Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n\n    ii. History of hysterectomy or bilateral salpingo-oophorectomy. iii. Ovarian failure (follicle stimulating hormone and estradiol in menopausal range, who have received whole pelvic radiation therapy).\n\n    iv. History of bilateral tubal ligation or another surgical sterilization procedure.\n\n    b. Approved methods of birth control are as follows: hormonal contraception (ie, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal Ligation or hysterectomy, subject/partner post-vasectomy, implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n13. Ability to understand and the willingness to sign a written informed consent document\n14. Signed and dated Institutional Review Board (IRB) approved informed consent form (ICF) before any protocol-directed Screening procedures are performed\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Prior organ allograft or prior cell therapy that included LDC or myeloablative chemotherapy regimen\n2. Known hypersensitivity to any component of KSQ-004EX or excipient including dimethyl sulfoxide, human serum albumin, LDC regimen (cyclophosphamide or fludarabine) or IL-2 (as applicable)\n3. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, Grade ≥ 2 colitis or Crohn's disease], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis], rheumatoid arthritis, etc.]). The following are exceptions to this criterion:\n\n   1. Participants with vitiligo or alopecia\n   2. Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement\n   3. Any chronic skin condition that does not require systemic therapy\n   4. Participants with celiac disease controlled by diet alone\n4. Hypersensitivity to antibiotics of the aminoglycoside group (eg, streptomycin, gentamicin) or penicillin\n5. Active, uncontrolled concurrent infection requiring IV antibiotics present at Screening\n6. Uveal and/or ocular melanoma\n7. Large cell neuroendocrine NSCLC (defined as pathology with >10% neuroendocrine components)\n8. Symptomatic and/or untreated brain metastases (of any size or number) including active leptomeningeal or parenchymal metastases.\n\n   Note: Participants with definitively treated brain metastases may be considered for enrollment if stable (defined as stable for 1-month post-central nervous system directed therapy) after discussion with the drug provider (KSQ)\n9. Participants with ascites\n10. Women who are pregnant or nursing\n11. Seropositive for human immunodeficiency virus (HIV) 1 or 2 or acquired immunodeficiency syndrome, or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) Note: Participants with positive HCV antibody may be eligible if HCV ribonucleic acid (RNA) is undetectable on a quantitative HCV RNA assay, following discussion with the drug provider (KSQ)\n12. Any form of primary immunodeficiency (eg, Severe Combined Immunodeficiency Disease)\n13. Any known clinically significant or concurrent acute liver disease, including viral hepatitis\n14. Previous solid organ or hematopoietic cell transplant\n15. Need for treatment with steroids at stable doses (> 10 mg/day prednisone or equivalent)\n\n    1. Topical, ophthalmic, or inhaled steroid medications are allowed\n    2. Systemic steroid (>10 mg/day) use is not allowed for 14 days prior to enrollment\n    3. Systemic steroids < 10 mg/day are permitted if for supplemental endocrine only Note: steroids can be administered for IV contrast allergy\n16. Live or unattenuated vaccine < 28 days prior to first dose of LDC regimen\n17. History of stroke, transient ischemic attack, unstable angina, or myocardial infarction, within 3 months prior to first dose of study treatment\n18. Symptomatic congestive heart failure according to New York Heart Association (NYHA) classification, Class III or IV (per NYHA Classification), unstable angina pectoris, clinically significant cardia arrhythmia, or left ventricular ejection fraction < 45%\n19. Prolongation of QT/QTc interval (QTc interval > 480 msec) using the Frederica method of QTc analysis\n20. Unable to walk a distance of 80% predicted for age and sex or develop hypoxia (SPO2 < 90%) during a 6-minute walk test (this test can be performed in place of pulmonary function test [PFT] for those unable to perform a reliable PFT due to complex upper airway anatomy)\n21. For participants receiving IL-2 only: evidence of ischemia on cardiac stress test\n22. > 80% stenosis based on carotid doppler ultrasound for patients with NSCLC and HNSCC with > 35 pack year smoking history\n23. Obstructive or restrictive pulmonary disease Note: Post-bronchodilator values: forced expiratory volume (FEV1)/forced vital capacity > 70% or FEV1 > 50% of predicted normal are required for study entry\n24. Suspected pneumonitis or interstitial lung disease (confirmed by radiography or computed tomography [CT])\n25. Treatment on another study with other investigational therapeutic interventional study within 28 days to start of LDC regimen\n26. Known additional malignancy that is active and/or progressive requiring treatment; exceptions including basal cell or squamous cell skin cancer, or other cancer for which the participants has been disease-free for at least 2 years\n27. Psychiatric illness/social situation that would limit compliance with study requirements, as determined by the Investigator\n28. Other severe, acute, or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of the study results, and in the judgement of the Investigator, would the participant inappropriate for the study",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "1. Diagnosed with one of the following tumor types:",
            "criterions": [
                {
                    "exact_snippets": "Diagnosed with one of the following tumor types",
                    "criterion": "tumor type diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "one of the following tumor types"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Adequate bone marrow function defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Life expectancy of ≥ 12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of ≥ 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Hemoglobin of ≥ 9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin of ≥ 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Up to 5 mucosal patients can be treated in the melanoma expansion cohort only.",
            "criterions": [
                {
                    "exact_snippets": "Up to 5 mucosal patients can be treated in the melanoma expansion cohort only.",
                    "criterion": "mucosal melanoma patients in melanoma expansion cohort",
                    "requirements": [
                        {
                            "requirement_type": "maximum number allowed",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "patients"
                            }
                        },
                        {
                            "requirement_type": "cohort restriction",
                            "expected_value": "melanoma expansion cohort only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "i. Participants with tumors that have known actionable molecular alteration such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS-1, B-Raf proto-oncogene (BRAF), rearranged during transfection (RET), MET and Kirsten Rat Sarcoma Virus (KRAS) must have progressed on standard directed molecular therapy in addition to platinum-based chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "tumors that have known actionable molecular alteration such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS-1, B-Raf proto-oncogene (BRAF), rearranged during transfection (RET), MET and Kirsten Rat Sarcoma Virus (KRAS)",
                    "criterion": "tumor molecular alteration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "EGFR",
                                "ALK",
                                "ROS-1",
                                "BRAF",
                                "RET",
                                "MET",
                                "KRAS"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have progressed on standard directed molecular therapy in addition to platinum-based chemotherapy",
                    "criterion": "progression on prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "progression_on_standard_molecular_therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression_on_platinum_based_chemotherapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Retreatment with the same class or previous class of treatment alone or in combination c. Locally advanced recurrent and/or metastatic histologically and/or cytologically confirmed HNSCC that has been previously treated with at least 1 and no more than 4 lines of prior therapy in the advanced/metastatic setting.",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced recurrent and/or metastatic histologically and/or cytologically confirmed HNSCC",
                    "criterion": "HNSCC (head and neck squamous cell carcinoma)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "locally advanced",
                                "recurrent",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has been previously treated with at least 1 and no more than 4 lines of prior therapy in the advanced/metastatic setting",
                    "criterion": "number of prior lines of therapy in advanced/metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Female participants who are women of childbearing potential (WOCP), (defined as physiologically and anatomically capable of becoming pregnant), confirmed of a negative pregnancy test and agreement to the use of a highly effective contraceptive method or at least 2 effective methods at the same time during study treatment period and for up to 3 months after study treatment (KSQ-004EX infusion). Male participants must be willing to use effective barrier contraception (ie, condoms) during the study treatment period and for up 3 months after study treatment (KSQ-004EX infusion)",
            "criterions": [
                {
                    "exact_snippets": "Female participants who are women of childbearing potential (WOCP), (defined as physiologically and anatomically capable of becoming pregnant)",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed of a negative pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement to the use of a highly effective contraceptive method or at least 2 effective methods at the same time during study treatment period and for up to 3 months after study treatment (KSQ-004EX infusion)",
                    "criterion": "contraceptive use (female)",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive method",
                            "expected_value": [
                                "highly effective method",
                                "at least 2 effective methods at the same time"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during study treatment period and for up to 3 months after study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Male participants must be willing to use effective barrier contraception (ie, condoms) during the study treatment period and for up 3 months after study treatment (KSQ-004EX infusion)",
                    "criterion": "contraceptive use (male)",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive method",
                            "expected_value": "effective barrier contraception (ie, condoms)"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the study treatment period and for up 3 months after study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Adequate hepatic function defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note, the following do not count towards a line of prior therapy:",
            "criterions": [
                {
                    "exact_snippets": "do not count towards a line of prior therapy",
                    "criterion": "line of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "counting",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any therapy/regimen discontinued due to intolerance/tolerability issues",
            "criterions": [
                {
                    "exact_snippets": "Any therapy/regimen discontinued due to intolerance/tolerability issues",
                    "criterion": "therapy/regimen discontinuation",
                    "requirements": [
                        {
                            "requirement_type": "reason for discontinuation",
                            "expected_value": [
                                "intolerance",
                                "tolerability issues"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Age ≥ 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Washout period from prior anticancer therapy(ies) of a minimum duration (excluding bridging therapy per concomitant medication, see Section 6.11) is required prior to the first study treatment (i.e., start of LDC therapy) as detailed below:",
            "criterions": [
                {
                    "exact_snippets": "Washout period from prior anticancer therapy(ies) of a minimum duration ... is required prior to the first study treatment",
                    "criterion": "washout period from prior anticancer therapies",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration",
                            "expected_value": "as detailed below"
                        }
                    ]
                }
            ]
        },
        {
            "line": "iv. History of bilateral tubal ligation or another surgical sterilization procedure.",
            "criterions": [
                {
                    "exact_snippets": "History of bilateral tubal ligation",
                    "criterion": "bilateral tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "another surgical sterilization procedure",
                    "criterion": "surgical sterilization procedure",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Monoclonal antibodies with a washout of at least 21 days or 5 half-lives or whichever is longer",
            "criterions": [
                {
                    "exact_snippets": "Monoclonal antibodies with a washout of at least 21 days or 5 half-lives or whichever is longer",
                    "criterion": "monoclonal antibody washout period",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 21,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Signed and dated Institutional Review Board (IRB) approved informed consent form (ICF) before any protocol-directed Screening procedures are performed",
            "criterions": [
                {
                    "exact_snippets": "Signed and dated Institutional Review Board (IRB) approved informed consent form (ICF) before any protocol-directed Screening procedures are performed",
                    "criterion": "informed consent form (ICF)",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "IRB approved",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "before any protocol-directed Screening procedures are performed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Adequate renal function defined as calculated creatinine clearance (Cockcroft-Gault) ≥ 40 mL/min",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function defined as calculated creatinine clearance (Cockcroft-Gault) ≥ 40 mL/min",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "creatinine clearance (Cockcroft-Gault)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Total bilirubin ≤ 2.0 × upper limit of normal (ULN) unless associated with Gilbert's syndrome",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 2.0 × upper limit of normal (ULN) unless associated with Gilbert's syndrome",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "× ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless associated with Gilbert's syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Radiation therapy: prior external beam radiation is allowed provided a minimum of 14 days have elapsed between the last dose of radiation and first study treatment (LDC)",
            "criterions": [
                {
                    "exact_snippets": "prior external beam radiation is allowed",
                    "criterion": "prior external beam radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a minimum of 14 days have elapsed between the last dose of radiation and first study treatment (LDC)",
                    "criterion": "interval between last dose of radiation and first study treatment",
                    "requirements": [
                        {
                            "requirement_type": "time interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. At least one measurable lesion per RECIST v1.1 (Eisenhauer 2009) following tumor resection for KSQ-004EX manufacturing Note: Lesions in previously irradiated areas should not be selected as a target lesion unless radiation treatment was ≥ 3 months prior, and there has been demonstrated disease progression in the lesion",
            "criterions": [
                {
                    "exact_snippets": "At least one measurable lesion per RECIST v1.1",
                    "criterion": "measurable lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": "per RECIST v1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Lesions in previously irradiated areas should not be selected as a target lesion unless radiation treatment was ≥ 3 months prior, and there has been demonstrated disease progression in the lesion",
                    "criterion": "lesion in previously irradiated area",
                    "requirements": [
                        {
                            "requirement_type": "radiation treatment interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Absolute neutrophil count (ANC) of ≥ 1 × 109/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) of ≥ 1 × 109/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "× 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Resectable lesion for KSQ-004EX manufacturing (tumor ≥ 1.5 cm2 or at least 5 core needle biopsies)",
            "criterions": [
                {
                    "exact_snippets": "Resectable lesion for KSQ-004EX manufacturing",
                    "criterion": "lesion resectability",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor ≥ 1.5 cm2",
                    "criterion": "tumor size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 5 core needle biopsies",
                    "criterion": "core needle biopsies",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "biopsies"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Chemotherapy: adjuvant, neoadjuvant or definitive chemotherapy/chemoradiation is allowed provided the washout is a minimum of 21 days or 5 half-lives, whichever is shorter",
            "criterions": [
                {
                    "exact_snippets": "adjuvant, neoadjuvant or definitive chemotherapy/chemoradiation is allowed",
                    "criterion": "prior chemotherapy or chemoradiation",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "adjuvant",
                                "neoadjuvant",
                                "definitive"
                            ]
                        },
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "provided the washout is a minimum of 21 days or 5 half-lives, whichever is shorter",
                    "criterion": "washout period after prior chemotherapy or chemoradiation",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 21,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Targeted therapy: prior targeted therapy with an EGFR, ALK, receptor tyrosine kinase, or other-directed agent (eg, erlotinib, afatinib, osimertinib, crizotinib, ceritinib), is allowed provided the washout is a minimum of 7 days or 5 half-lives, whichever is longer prior to start of therapy (LDC)",
            "criterions": [
                {
                    "exact_snippets": "prior targeted therapy with an EGFR, ALK, receptor tyrosine kinase, or other-directed agent (eg, erlotinib, afatinib, osimertinib, crizotinib, ceritinib), is allowed provided the washout is a minimum of 7 days or 5 half-lives, whichever is longer prior to start of therapy (LDC)",
                    "criterion": "prior targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "agent type",
                            "expected_value": [
                                "EGFR-directed",
                                "ALK-directed",
                                "receptor tyrosine kinase-directed",
                                "other-directed (eg, erlotinib, afatinib, osimertinib, crizotinib, ceritinib)"
                            ]
                        },
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 7,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii. History of hysterectomy or bilateral salpingo-oophorectomy. iii. Ovarian failure (follicle stimulating hormone and estradiol in menopausal range, who have received whole pelvic radiation therapy).",
            "criterions": [
                {
                    "exact_snippets": "History of hysterectomy",
                    "criterion": "hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bilateral salpingo-oophorectomy",
                    "criterion": "bilateral salpingo-oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Ovarian failure (follicle stimulating hormone and estradiol in menopausal range, who have received whole pelvic radiation therapy)",
                    "criterion": "ovarian failure",
                    "requirements": [
                        {
                            "requirement_type": "hormone levels",
                            "expected_value": [
                                "follicle stimulating hormone in menopausal range",
                                "estradiol in menopausal range"
                            ]
                        },
                        {
                            "requirement_type": "history of radiation therapy",
                            "expected_value": "whole pelvic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Surgery: previous surgical procedure(s) is permitted provided that wound healing has occurred and at least 14 days have elapsed (for major operative procedures) prior to the first study treatment (LDC)",
            "criterions": [
                {
                    "exact_snippets": "previous surgical procedure(s) is permitted",
                    "criterion": "previous surgical procedures",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "wound healing has occurred",
                    "criterion": "wound healing",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healed"
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 14 days have elapsed (for major operative procedures) prior to the first study treatment (LDC)",
                    "criterion": "time since major operative procedure",
                    "requirements": [
                        {
                            "requirement_type": "elapsed_time_since_procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "e. Locally advanced, recurrent, or metastatic histologically and/or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced, recurrent, or metastatic ... pancreatic ductal adenocarcinoma (PDAC)",
                    "criterion": "pancreatic ductal adenocarcinoma (PDAC)",
                    "requirements": [
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "locally advanced",
                                "recurrent",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically and/or cytologically confirmed",
                    "criterion": "pancreatic ductal adenocarcinoma (PDAC)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting",
                    "criterion": "prior therapy lines in advanced/metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapy lines",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Histologically and/or cytologically confirmed primary diagnosis of NSCLC which has progressed on at least 1 line and no more than 4 lines of prior therapy in the advanced/metastatic setting, including platinum-based chemotherapy and checkpoint inhibitor therapy (either given in combination or sequentially).",
            "criterions": [
                {
                    "exact_snippets": "Histologically and/or cytologically confirmed primary diagnosis of NSCLC",
                    "criterion": "NSCLC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "diagnosis type",
                            "expected_value": "primary"
                        }
                    ]
                },
                {
                    "exact_snippets": "progressed on at least 1 line and no more than 4 lines of prior therapy in the advanced/metastatic setting",
                    "criterion": "prior therapy lines in advanced/metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapy lines",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including platinum-based chemotherapy and checkpoint inhibitor therapy (either given in combination or sequentially)",
                    "criterion": "prior therapies received",
                    "requirements": [
                        {
                            "requirement_type": "therapy types received",
                            "expected_value": [
                                "platinum-based chemotherapy",
                                "checkpoint inhibitor therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Recovered to ≤ Grade 1 or Baseline toxicity (except alopecia, neuropathy, and endocrinopathies from prior immunotherapy) from prior therapy (per the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE])",
            "criterions": [
                {
                    "exact_snippets": "Recovered to ≤ Grade 1 or Baseline toxicity ... from prior therapy (per the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE])",
                    "criterion": "toxicity from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "Grade"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "baseline"
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia, neuropathy, and endocrinopathies from prior immunotherapy",
                    "criterion": "alopecia from prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from toxicity recovery requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia, neuropathy, and endocrinopathies from prior immunotherapy",
                    "criterion": "neuropathy from prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from toxicity recovery requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia, neuropathy, and endocrinopathies from prior immunotherapy",
                    "criterion": "endocrinopathies from prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from toxicity recovery requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (or ≤ 5 × ULN in patients with liver metastases)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... ≤ 3.0 × ULN (or ≤ 5 × ULN in patients with liver metastases)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... ≤ 3.0 × ULN (or ≤ 5 × ULN in patients with liver metastases)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≤ 5 × ULN in patients with liver metastases",
                    "criterion": "aspartate aminotransferase (AST) level in patients with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≤ 5 × ULN in patients with liver metastases",
                    "criterion": "alanine aminotransferase (ALT) level in patients with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following: i. Postmenopausal (no menses in greater than or equal to 12 consecutive months).",
            "criterions": [
                {
                    "exact_snippets": "all female participants",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "between the onset of menses (as early as 8 years of age) and 55 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 55,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "onset of menses",
                    "criterion": "menarche status",
                    "requirements": [
                        {
                            "requirement_type": "menarche_status",
                            "expected_value": "post-menarche"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the participant presents with an applicable exclusionary factor ... Postmenopausal (no menses in greater than or equal to 12 consecutive months)",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "menopausal_status",
                            "expected_value": "not postmenopausal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "f. Recurrent, metastatic, or persistent histologically and/or cytologically confirmed squamous cell carcinoma (SCC), adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting.",
            "criterions": [
                {
                    "exact_snippets": "histologically and/or cytologically confirmed squamous cell carcinoma (SCC), adenosquamous carcinoma, or adenocarcinoma of the cervix",
                    "criterion": "cervical cancer type",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation",
                            "expected_value": [
                                "histologically confirmed",
                                "cytologically confirmed"
                            ]
                        },
                        {
                            "requirement_type": "histology subtype",
                            "expected_value": [
                                "squamous cell carcinoma",
                                "adenosquamous carcinoma",
                                "adenocarcinoma"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Recurrent, metastatic, or persistent ... carcinoma",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "recurrent",
                                "metastatic",
                                "persistent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not amenable to curative treatment with surgery and/or radiation therapy",
                    "criterion": "amenability to curative treatment",
                    "requirements": [
                        {
                            "requirement_type": "curative treatment amenability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting",
                    "criterion": "prior lines of therapy in advanced/metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapy lines",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "i. Participants must have received a platinum-containing chemotherapy regimen for the treatment of primary tumor in locally advanced, or metastatic setting d. Advanced, metastatic histologically and/or cytologically confirmed colorectal adenocarcinoma that has progressed following at least 1 and no more than 3 lines of prior therapy. Participants with dMMR/MSI-H or KRASG12C BRAF V600E mutation must have progressed on standard directed therapy.",
            "criterions": [
                {
                    "exact_snippets": "Participants must have received a platinum-containing chemotherapy regimen for the treatment of primary tumor in locally advanced, or metastatic setting",
                    "criterion": "prior platinum-containing chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "primary tumor in locally advanced setting",
                                "primary tumor in metastatic setting"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Advanced, metastatic histologically and/or cytologically confirmed colorectal adenocarcinoma",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "colorectal adenocarcinoma that has progressed following at least 1 and no more than 3 lines of prior therapy",
                    "criterion": "progression after prior therapy lines",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapy lines",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with dMMR/MSI-H or KRASG12C BRAF V600E mutation must have progressed on standard directed therapy",
                    "criterion": "dMMR/MSI-H or KRASG12C or BRAF V600E mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": [
                                "dMMR/MSI-H",
                                "KRASG12C",
                                "BRAF V600E"
                            ]
                        },
                        {
                            "requirement_type": "progression on standard directed therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Unresectable, incurable and/or metastatic histologically and/or cytologically confirmed cutaneous, acral, or unknown primary melanoma (Stage IIIC or Stage IV) that has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting, one of which includes treatment with anti-PD-1/PD-L1 inhibitor alone or in combination with anti-cytotoxic T lymphocyte associated protein 4 (anti-CTLA-4) inhibitor or in combination with anti-LAG-3 antibody.",
            "criterions": [
                {
                    "exact_snippets": "Unresectable, incurable and/or metastatic ... melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "cutaneous",
                                "acral",
                                "unknown primary"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Unresectable, incurable and/or metastatic",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "unresectable",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "incurable",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "metastatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically and/or cytologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage IIIC or Stage IV",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "IIIC",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed following at least 1 and no more than 3 lines of prior therapy in the advanced/metastatic setting",
                    "criterion": "prior lines of therapy in advanced/metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "one of which includes treatment with anti-PD-1/PD-L1 inhibitor alone or in combination with anti-cytotoxic T lymphocyte associated protein 4 (anti-CTLA-4) inhibitor or in combination with anti-LAG-3 antibody",
                    "criterion": "prior therapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "contains",
                            "expected_value": [
                                "anti-PD-1/PD-L1 inhibitor alone",
                                "anti-PD-1/PD-L1 inhibitor in combination with anti-CTLA-4 inhibitor",
                                "anti-PD-1/PD-L1 inhibitor in combination with anti-LAG-3 antibody"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "b. Approved methods of birth control are as follows: hormonal contraception (ie, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal Ligation or hysterectomy, subject/partner post-vasectomy, implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",
            "criterions": [
                {
                    "exact_snippets": "Approved methods of birth control are as follows: hormonal contraception (ie, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal Ligation or hysterectomy, subject/partner post-vasectomy, implantable or injectable contraceptives, and condoms plus spermicide.",
                    "criterion": "birth control method",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "hormonal contraception",
                                "intrauterine device (IUD)",
                                "tubal ligation",
                                "hysterectomy",
                                "subject/partner post-vasectomy",
                                "implantable contraceptives",
                                "injectable contraceptives",
                                "condoms plus spermicide"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice",
                    "criterion": "sexual activity during trial and drug washout period",
                    "requirements": [
                        {
                            "requirement_type": "abstinence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control",
                    "criterion": "birth control method",
                    "requirements": [
                        {
                            "requirement_type": "excluded methods",
                            "expected_value": [
                                "periodic abstinence",
                                "rhythm method",
                                "withdrawal method"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",
                    "criterion": "pregnancy during study participation",
                    "requirements": [
                        {
                            "requirement_type": "reporting",
                            "expected_value": "must inform treating physician immediately"
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Ability to understand and the willingness to sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "Note: Participants with definitively treated brain metastases may be considered for enrollment if stable (defined as stable for 1-month post-central nervous system directed therapy) after discussion with the drug provider (KSQ)",
            "criterions": [
                {
                    "exact_snippets": "definitively treated brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "definitively treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "stable (defined as stable for 1-month post-central nervous system directed therapy)",
                    "criterion": "brain metastases stability",
                    "requirements": [
                        {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        },
                        {
                            "requirement_type": "post-therapy status",
                            "expected_value": "post-central nervous system directed therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Unable to walk a distance of 80% predicted for age and sex or develop hypoxia (SPO2 < 90%) during a 6-minute walk test (this test can be performed in place of pulmonary function test [PFT] for those unable to perform a reliable PFT due to complex upper airway anatomy)",
            "criterions": [
                {
                    "exact_snippets": "Unable to walk a distance of 80% predicted for age and sex ... during a 6-minute walk test",
                    "criterion": "6-minute walk test distance",
                    "requirements": [
                        {
                            "requirement_type": "performance",
                            "expected_value": {
                                "operator": "<",
                                "value": 80,
                                "unit": "% predicted for age and sex"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "develop hypoxia (SPO2 < 90%) during a 6-minute walk test",
                    "criterion": "oxygen saturation during 6-minute walk test",
                    "requirements": [
                        {
                            "requirement_type": "oxygen saturation",
                            "expected_value": {
                                "operator": "<",
                                "value": 90,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement",
            "criterions": [
                {
                    "exact_snippets": "Participants with hypothyroidism (eg, following Hashimoto syndrome)",
                    "criterion": "hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stable on hormone replacement",
                    "criterion": "hormone replacement therapy for hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, Grade ≥ 2 colitis or Crohn's disease], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis], rheumatoid arthritis, etc.]). The following are exceptions to this criterion:",
            "criterions": [
                {
                    "exact_snippets": "Active or prior documented autoimmune or inflammatory disorders",
                    "criterion": "autoimmune or inflammatory disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "prior"
                            ]
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inflammatory bowel disease [eg, Grade ≥ 2 colitis or Crohn's disease]",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade ≥ 2 colitis",
                    "criterion": "colitis",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Crohn's disease",
                    "criterion": "Crohn's disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic lupus erythematosus",
                    "criterion": "systemic lupus erythematosus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sarcoidosis syndrome",
                    "criterion": "sarcoidosis syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Wegener syndrome [granulomatosis with polyangiitis]",
                    "criterion": "Wegener syndrome (granulomatosis with polyangiitis)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "rheumatoid arthritis",
                    "criterion": "rheumatoid arthritis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Participants with ascites",
            "criterions": [
                {
                    "exact_snippets": "Participants with ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Previous solid organ or hematopoietic cell transplant",
            "criterions": [
                {
                    "exact_snippets": "Previous solid organ or hematopoietic cell transplant",
                    "criterion": "history of transplant",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "solid organ",
                                "hematopoietic cell"
                            ]
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "26. Known additional malignancy that is active and/or progressive requiring treatment; exceptions including basal cell or squamous cell skin cancer, or other cancer for which the participants has been disease-free for at least 2 years",
            "criterions": [
                {
                    "exact_snippets": "Known additional malignancy that is active and/or progressive requiring treatment",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "active",
                                "progressive"
                            ]
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "exceptions including basal cell or squamous cell skin cancer, or other cancer for which the participants has been disease-free for at least 2 years",
                    "criterion": "exception malignancies",
                    "requirements": [
                        {
                            "requirement_type": "malignancy type",
                            "expected_value": [
                                "basal cell skin cancer",
                                "squamous cell skin cancer"
                            ]
                        },
                        {
                            "requirement_type": "disease-free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "27. Psychiatric illness/social situation that would limit compliance with study requirements, as determined by the Investigator",
            "criterions": [
                {
                    "exact_snippets": "Psychiatric illness/social situation that would limit compliance with study requirements",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                },
                {
                    "exact_snippets": "Psychiatric illness/social situation that would limit compliance with study requirements",
                    "criterion": "social situation",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by the Investigator",
                    "criterion": "investigator assessment",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "as determined by the Investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "25. Treatment on another study with other investigational therapeutic interventional study within 28 days to start of LDC regimen",
            "criterions": [
                {
                    "exact_snippets": "Treatment on another study with other investigational therapeutic interventional study within 28 days to start of LDC regimen",
                    "criterion": "treatment on another investigational therapeutic interventional study",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Hypersensitivity to antibiotics of the aminoglycoside group (eg, streptomycin, gentamicin) or penicillin",
            "criterions": [
                {
                    "exact_snippets": "Hypersensitivity to antibiotics of the aminoglycoside group (eg, streptomycin, gentamicin)",
                    "criterion": "hypersensitivity to aminoglycoside antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hypersensitivity to ... penicillin",
                    "criterion": "hypersensitivity to penicillin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Large cell neuroendocrine NSCLC (defined as pathology with >10% neuroendocrine components)",
            "criterions": [
                {
                    "exact_snippets": "Large cell neuroendocrine NSCLC",
                    "criterion": "large cell neuroendocrine NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pathology with >10% neuroendocrine components",
                    "criterion": "neuroendocrine component percentage in pathology",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "24. Suspected pneumonitis or interstitial lung disease (confirmed by radiography or computed tomography [CT])",
            "criterions": [
                {
                    "exact_snippets": "Suspected pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "radiography",
                                "computed tomography (CT)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "interstitial lung disease (confirmed by radiography or computed tomography [CT])",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "radiography",
                                "computed tomography (CT)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Known hypersensitivity to any component of KSQ-004EX or excipient including dimethyl sulfoxide, human serum albumin, LDC regimen (cyclophosphamide or fludarabine) or IL-2 (as applicable)",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any component of KSQ-004EX",
                    "criterion": "hypersensitivity to KSQ-004EX components",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity to any ... excipient including dimethyl sulfoxide",
                    "criterion": "hypersensitivity to dimethyl sulfoxide",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity to any ... excipient including ... human serum albumin",
                    "criterion": "hypersensitivity to human serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity to any ... LDC regimen (cyclophosphamide or fludarabine)",
                    "criterion": "hypersensitivity to LDC regimen (cyclophosphamide or fludarabine)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity to any ... IL-2 (as applicable)",
                    "criterion": "hypersensitivity to IL-2",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Any form of primary immunodeficiency (eg, Severe Combined Immunodeficiency Disease)",
            "criterions": [
                {
                    "exact_snippets": "Any form of primary immunodeficiency (eg, Severe Combined Immunodeficiency Disease)",
                    "criterion": "primary immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Any chronic skin condition that does not require systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Any chronic skin condition that does not require systemic therapy",
                    "criterion": "chronic skin condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic therapy requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Topical, ophthalmic, or inhaled steroid medications are allowed",
            "criterions": [
                {
                    "exact_snippets": "Topical, ophthalmic, or inhaled steroid medications are allowed",
                    "criterion": "use of topical, ophthalmic, or inhaled steroid medications",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior organ allograft or prior cell therapy that included LDC or myeloablative chemotherapy regimen",
            "criterions": [
                {
                    "exact_snippets": "Prior organ allograft",
                    "criterion": "organ allograft",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior cell therapy that included LDC or myeloablative chemotherapy regimen",
                    "criterion": "cell therapy including LDC or myeloablative chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Active, uncontrolled concurrent infection requiring IV antibiotics present at Screening",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled concurrent infection requiring IV antibiotics present at Screening",
                    "criterion": "concurrent infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring IV antibiotics"
                        },
                        {
                            "requirement_type": "presence_at_screening",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. History of stroke, transient ischemic attack, unstable angina, or myocardial infarction, within 3 months prior to first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "History of stroke ... within 3 months prior to first dose of study treatment",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... transient ischemic attack ... within 3 months prior to first dose of study treatment",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... unstable angina ... within 3 months prior to first dose of study treatment",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... myocardial infarction ... within 3 months prior to first dose of study treatment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Symptomatic and/or untreated brain metastases (of any size or number) including active leptomeningeal or parenchymal metastases.",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic and/or untreated brain metastases (of any size or number)",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "active leptomeningeal or parenchymal metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active leptomeningeal or parenchymal metastases",
                    "criterion": "parenchymal metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Any known clinically significant or concurrent acute liver disease, including viral hepatitis",
            "criterions": [
                {
                    "exact_snippets": "Any known clinically significant or concurrent acute liver disease",
                    "criterion": "acute liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "including viral hepatitis",
                    "criterion": "viral hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Women who are pregnant or nursing",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are ... nursing",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Symptomatic congestive heart failure according to New York Heart Association (NYHA) classification, Class III or IV (per NYHA Classification), unstable angina pectoris, clinically significant cardia arrhythmia, or left ventricular ejection fraction < 45%",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic congestive heart failure according to New York Heart Association (NYHA) classification, Class III or IV (per NYHA Classification)",
                    "criterion": "congestive heart failure (NYHA classification)",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardia arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "left ventricular ejection fraction < 45%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Uveal and/or ocular melanoma",
            "criterions": [
                {
                    "exact_snippets": "Uveal and/or ocular melanoma",
                    "criterion": "melanoma type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "uveal",
                                "ocular"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. Obstructive or restrictive pulmonary disease Note: Post-bronchodilator values: forced expiratory volume (FEV1)/forced vital capacity > 70% or FEV1 > 50% of predicted normal are required for study entry",
            "criterions": [
                {
                    "exact_snippets": "Obstructive or restrictive pulmonary disease",
                    "criterion": "pulmonary disease type",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": [
                                "obstructive",
                                "restrictive"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Post-bronchodilator values: forced expiratory volume (FEV1)/forced vital capacity > 70%",
                    "criterion": "FEV1/FVC ratio (post-bronchodilator)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "FEV1 > 50% of predicted normal",
                    "criterion": "FEV1 (post-bronchodilator, % of predicted normal)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Need for treatment with steroids at stable doses (> 10 mg/day prednisone or equivalent)",
            "criterions": [
                {
                    "exact_snippets": "Need for treatment with steroids at stable doses (> 10 mg/day prednisone or equivalent)",
                    "criterion": "steroid treatment",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Systemic steroids < 10 mg/day are permitted if for supplemental endocrine only Note: steroids can be administered for IV contrast allergy",
            "criterions": [
                {
                    "exact_snippets": "Systemic steroids < 10 mg/day are permitted if for supplemental endocrine only",
                    "criterion": "systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "supplemental endocrine"
                        }
                    ]
                },
                {
                    "exact_snippets": "steroids can be administered for IV contrast allergy",
                    "criterion": "steroid administration for IV contrast allergy",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": "IV contrast allergy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. For participants receiving IL-2 only: evidence of ischemia on cardiac stress test",
            "criterions": [
                {
                    "exact_snippets": "For participants receiving IL-2 only: evidence of ischemia on cardiac stress test",
                    "criterion": "ischemia on cardiac stress test",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Participants with celiac disease controlled by diet alone",
            "criterions": [
                {
                    "exact_snippets": "Participants with celiac disease",
                    "criterion": "celiac disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "controlled by diet alone",
                    "criterion": "celiac disease control method",
                    "requirements": [
                        {
                            "requirement_type": "control method",
                            "expected_value": "diet alone"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participants with vitiligo or alopecia",
            "criterions": [
                {
                    "exact_snippets": "Participants with vitiligo",
                    "criterion": "vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with ... alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Systemic steroid (>10 mg/day) use is not allowed for 14 days prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Systemic steroid (>10 mg/day) use is not allowed for 14 days prior to enrollment",
                    "criterion": "systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "22. > 80% stenosis based on carotid doppler ultrasound for patients with NSCLC and HNSCC with > 35 pack year smoking history",
            "criterions": [
                {
                    "exact_snippets": "> 80% stenosis based on carotid doppler ultrasound",
                    "criterion": "carotid artery stenosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 80,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "carotid doppler ultrasound"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with NSCLC",
                    "criterion": "non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with ... HNSCC",
                    "criterion": "head and neck squamous cell carcinoma (HNSCC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "> 35 pack year smoking history",
                    "criterion": "smoking history",
                    "requirements": [
                        {
                            "requirement_type": "pack years",
                            "expected_value": {
                                "operator": ">",
                                "value": 35,
                                "unit": "pack year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Seropositive for human immunodeficiency virus (HIV) 1 or 2 or acquired immunodeficiency syndrome, or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) Note: Participants with positive HCV antibody may be eligible if HCV ribonucleic acid (RNA) is undetectable on a quantitative HCV RNA assay, following discussion with the drug provider (KSQ)",
            "criterions": [
                {
                    "exact_snippets": "Seropositive for human immunodeficiency virus (HIV) 1 or 2",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acquired immunodeficiency syndrome",
                    "criterion": "acquired immunodeficiency syndrome (AIDS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection with hepatitis B virus (HBV)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection with ... hepatitis C virus (HCV)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with positive HCV antibody may be eligible if HCV ribonucleic acid (RNA) is undetectable on a quantitative HCV RNA assay",
                    "criterion": "HCV ribonucleic acid (RNA)",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Prolongation of QT/QTc interval (QTc interval > 480 msec) using the Frederica method of QTc analysis",
            "criterions": [
                {
                    "exact_snippets": "Prolongation of QT/QTc interval (QTc interval > 480 msec)",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "using the Frederica method of QTc analysis",
                    "criterion": "QTc analysis method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "Frederica"
                        }
                    ]
                }
            ]
        },
        {
            "line": "28. Other severe, acute, or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of the study results, and in the judgement of the Investigator, would the participant inappropriate for the study",
            "criterions": [
                {
                    "exact_snippets": "Other severe, acute, or chronic medical condition",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "severe",
                                "acute",
                                "chronic"
                            ]
                        },
                        {
                            "requirement_type": "risk_increase_with_study_participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory abnormality that may increase the risk associated with study participation or study drug administration",
                    "criterion": "laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "risk_increase_with_study_participation_or_drug_administration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "medical condition ... that may interfere with the interpretation of the study results",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "interference_with_study_result_interpretation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the judgement of the Investigator, would the participant inappropriate for the study",
                    "criterion": "appropriateness for study participation (per Investigator judgment)",
                    "requirements": [
                        {
                            "requirement_type": "investigator_judgment_inappropriateness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Live or unattenuated vaccine < 28 days prior to first dose of LDC regimen",
            "criterions": [
                {
                    "exact_snippets": "Live or unattenuated vaccine < 28 days prior to first dose of LDC regimen",
                    "criterion": "live or unattenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration before first dose of LDC regimen",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "2. Platelet count of ≥ 100.0 × 109/L",
            "criterions": [
                {
                    "exact_snippets": "Platelet count of ≥ 100.0 × 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100.0,
                                "unit": "× 10^9/L"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}